Santarus to Present at Leerink Swann Global Healthcare Conference
SAN DIEGO -- February 6, 2013
Santarus, Inc. (NASDAQ: SNTS) today announced that Debra P. Crawford, senior
vice president and chief financial officer, will make a presentation at the
Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013, at
1:30 p.m. Eastern time (10:30 a.m. Pacific time) in New York City.
A webcast of the presentation will be available during the event at
www.santarus.com and will be archived and available on the website for 14
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring,
developing and commercializing proprietary products that address the needs of
patients treated by physician specialists. The company's current commercial
efforts are focused on GLUMETZA^® (metformin hydrochloride extended release
tablets) and CYCLOSET^® (bromocriptine mesylate) tablets, which are indicated
as adjuncts to diet and exercise to improve glycemic control in adults with
type 2 diabetes, and on FENOGLIDE^® (fenofibrate) tablets, which is indicated
as an adjunct to diet to reduce high cholesterol. In mid-February 2013, the
company plans to begin promoting UCERIS^™ (budesonide) extended release
tablets for the induction of remission of active, mild to moderate ulcerative
colitis and ZEGERID^® (omeprazole/sodium bicarbonate) for the treatment of
certain upper gastrointestinal disorders. Full prescribing and safety
information for Santarus’ products are available at www.santarus.com.
Santarus’ product development pipeline includes the investigational drug
RUCONEST^® (recombinant human C1 esterase inhibitor) for treatment of acute
attacks of hereditary angioedema. The company expects to submit a biologics
license application (BLA) to the U.S. Food and Drug Administration for
RUCONEST in the first half of 2013. Santarus is also developing rifamycin SV
MMX^®, which is in Phase III clinical testing for treatment of travelers’
diarrhea. In addition, enrollment has been completed in a Phase I clinical
program with SAN-300, the company’s investigational monoclonal antibody. More
information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation by Santarus that any of its plans will be achieved. Actual
results may differ materially from those set forth in this release due to the
risks and uncertainties inherent in Santarus’ business, including, without
limitation: difficulties or delays in development, testing, manufacturing and
marketing of, and obtaining and maintaining regulatory approvals for,
Santarus’ products; and other risks detailed in Santarus’ prior press releases
as well as in public periodic filings with the Securities and Exchange
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Santarus undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof. This caution is made
under the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
Santarus^®, FENOGLIDE^®, UCERIS^™ and ZEGERID^® are trademarks of Santarus,
Inc. GLUMETZA^® is a trademark of Biovail Laboratories International S.r.l.
licensed exclusively in the United States to Depomed, Inc. CYCLOSET^® is a
trademark of VeroScience LLC. MMX^® is a trademark of Cosmo Technologies
Limited. RUCONEST^® is a trademark of Pharming Group N.V.
Martha L. Hough
VP Finance & Investor Relations
Debra P. Crawford
Chief Financial Officer
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Press spacebar to pause and continue. Press esc to stop.